| 0.02 0.004 (27.39%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
BIOLASE, Inc., along with its various divisions, operates as a global enterprise specializing in the creation, production, distribution, and sale of advanced laser systems. These technologies are specifically designed for dental professionals and their patients across the United States and internationally. The sophisticated laser instruments developed by BIOLASE empower a diverse array of dental specialists—including general dentists, periodontists, endodontists, and oral surgeons—to execute a broad spectrum of minimally invasive procedures. These applications range from cosmetic enhancements and restorative treatments to intricate surgical interventions. Among its core product offerings, the company provides Waterlase all-tissue dental laser systems, which are highly effective for precisely cutting both soft and hard tissues. It also supplies diode soft-tissue laser systems, utilized for procedures involving soft tissue, pain management, teeth whitening, and various other aesthetic treatments. Furthermore, the Epic Hygiene laser assists in addressing non-surgical periodontitis and enhancing overall clinical efficiency. Beyond its primary laser devices, BIOLASE also manufactures and distributes essential consumable items and accessories. This comprehensive range includes flexible fibers, specialized hand pieces, and professional teeth whitening gel kits. The company markets its products through a dedicated in-house sales team and an extensive network of distributors. Established in 1984, the organization was initially known as BIOLASE Technology, Inc., before officially changing its name to BIOLASE, Inc. in 2012. Its corporate headquarters are situated in Foothill Ranch, California.
Tue, 18 Jun 2024
BIOLASE Announces Delisting from Nasdaq - Stock Titan
Thu, 15 Feb 2024
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering - Yahoo Finance
Mon, 06 Jun 2022
BIOLASE SIGNS LEASE TO EXPAND TRAINING AND EDUCATION INITIATIVES - PR Newswire
Thu, 06 Jan 2022
BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New Device - Dentistry Today
Thu, 25 Mar 2021
BIOLASE (BIOL) Stock Live Price, Chart & News - CoinCodex
Mon, 15 Mar 2021
BIOLASE (BIOL) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|